TMCnet News
Vensun Pharmaceuticals, Inc. Appoints Joan Janulis as the SVP of Regulatory Affairs and ComplianceVensun Pharmaceuticals, Inc. ("Vensun" or "the Company"), a privately held generic pharmaceutical company, today announced the appointment of Joan Janulis as the Senior Vice President of Regulatory Affairs and Compliance. In this role Ms. Janulis will oversee the regulatory affairs, quality, and compliance functions. Ms. Janulis is a highly experienced pharmaceutical executive with extensive knowledge of U.S. Food and Drug Administration (FDA) regulations, guidance and best practices. Ms. Janulis was most recently a Vice President and Head of the Regulatory Practice at Lachman Consultants, a premier pharmaceutical consulting company. She also served on Lachman's board of directors for the past 3 years. In acknowledging this senior management team appointment, Hem Pandya, President and CEO said, "I am pleased to be reunited with Joan having had the privilege of working with her over the past several years. Her wealth of experience and successful track record will be of tremendous value to Vensun as we approach the FDA Target (News - Alert) ction Dates (TADs) for our 20 accepted ANDAs." "I am excited to join the talented team at Vensun," commented Ms. Janulis. "I look forward to the challenges of getting our multiple ANDAs approved in a timely manner, while continuously engaging with our strategic partners to maintain Vensun's quality and compliance standards." Prior to joining Lachman, Ms. Janulis has held various executive positions at Faulding/Purepac Pharmaceutical (now Actavis), Ivax Pharmaceuticals (now Teva), and Able Laboratories. Ms. Janulis holds a Bachelor of Science degree in Chemical Engineering from the New Jersey Institute of Technology, and has been maintained a Regulatory Affairs Certification (RAC) for over 20 years. About Vensun Pharmaceuticals, Inc. Vensun Pharmaceuticals, Inc., based in Yardley, Pennsylvania, was established in July 2011 and is an emerging pharmaceutical company developing a portfolio of generic prescription products in various dosage forms covering a broad range of therapeutic categories. The Company is co-developing the products with a number of strategic partners in the US and overseas. The Company has over 20 filed ANDAs and 14 products in active development. Vensun has also in-licensed 24 products to expand and diversify its pipeline. For more information regarding Vensun Pharmaceuticals, Inc., please visit www.vensunrx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160212005396/en/ |
